Treating Cancer with Bispecific Antibody Therapy in New Jersey
New Jersey Cancer Care, PA delivers leading‑edge cancer care, tailored to you.
New Jersey Cancer Care
Bispecific antibody therapy is a groundbreaking advancement in cancer treatment that targets cancer cells using the patient’s immune system. This therapy is an innovative treatment option for patients with conditions that may be resistant to other treatment options.
Bispecific antibodies represent one of the most significant advances in cancer treatment in recent years. These innovative therapies help your own immune system recognize and attack cancer cells while allowing many patients to receive treatment without hospitalization.
What Are Bispecific Antibodies?
Bispecific antibodies are a type of immunotherapy designed to recognize two different targets at the same time.
One part of the antibody attaches to a cancer cell, while the other attaches to one of your body’s immune cells (called a T-cell). By bringing these cells together, the treatment helps activate your immune system to identify and destroy cancer cells.
Unlike chemotherapy, which attacks rapidly dividing cells, bispecific antibodies work by directing your own immune system to fight cancer.
Benefits of Bispecific Antibody Therapy
- Targeted, Precise Immune Response: Bispecific antibodies directly bind immune cells to cancer cells, facilitating a more accurate immune response.
- Improved Outcomes: Studies show that bispecific antibodies have improved outcomes for multiple cancer types, including small cell lung cancer and blood cancers.
- Streamlined Treatment: Bispecific antibodies are off-the-shelf therapies, which are more readily available for patients.
How Do Bispecific Antibodies Work?
Bispecific antibodies work by directing the patient’s T cells to the cancers cells, helping the immune system work more effectively.
Once the antibodies are delivered into the body, they bind to two targets—one side attaches to the cancer cell, and the other connects with the T cell—bringing them together to trigger a more focused immune response.
Bispecific antibodies can be administered by injection or infusion, either in a hospital or at an outpatient infusion center. During initial treatments, patients receive gradually increasing doses to help minimize side effects. After this phase, treatments typically continue at regular dosing intervals.
Cancers Treated with Bispecific Antibodies
Bispecific antibodies are available to patients diagnosed with the following cancers:
- Acute Lymphoblastic Leukemia
- Uveal Melanoma
- Diffuse Large B-Cell Lymphoma
- Follicular Lymphoma
- Extensive-Stage Lung Cancer
Side Effects
Like all cancer treatments, bispecific therapy may come with some side effects, including:
- Fever and chills, especially after your first few doses
- Fatigue that may last a few days after treatment
- Mild stomach upset, nausea, or headaches
Less common but serious side effects include Cytokine Release Syndrome (CRS) (a temporary immune reaction that can cause fever, low blood pressure or difficulty breathing), neurological symptoms, infections, and low blood counts.
If you have questions about bispecific therapy or its potent side effects, please consult your provider or contact our care team at our Belleville, or Montclair offices.
Important Safety Information
Because bispecific antibodies activate the immune system, they can occasionally cause serious side effects that require prompt medical attention.
These include:
Cytokine Release Syndrome (CRS)
CRS is an inflammatory response that may occur during the first few doses of treatment.
Symptoms may include:
- Fever
- Chills
- Low blood pressure
- Rapid heart rate
- Difficulty breathing
Neurologic Side Effects (ICANS)
Although less common, some patients may experience neurologic symptoms such as:
- Confusion
- Difficulty speaking
- Tremors
- Sleepiness
- Headache
- Changes in handwriting or coordination
Infection Risk
Some bispecific therapies can temporarily weaken the immune system, increasing the risk of infection. Your provider may prescribe preventive medications to help reduce this risk.
Our clinical team follows nationally recognized treatment protocols and monitors patients closely throughout therapy to identify and manage side effects as early as possible.
Frequently Asked Questions
What is bispecific antibody therapy?
Bispecific antibody therapy is an innovative cancer treatment that attaches to both a cancer cell and a T cell simultaneously. This physical bridge directs the patient’s immune system to precisely target and eliminate cancer cells.
How are bispecific antibodies administered?
Bispecific antibodies are administered by injection or IV infusion in a hospital or at an outpatient infusion center. Patients typically begin with gradually increasing doses (“step-up dosing”) to reduce side effects before transitioning to regular dosing intervals.
Which cancers can be treated with bispecific antibodies at New Jersey Cancer Care?
Bispecific antibody therapy is available for patients diagnosed with Acute Lymphoblastic Leukemia, Uveal Melanoma, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Multiple Myeloma, and Extensive-Stage Lung Cancer.
What are the main benefits of bispecific antibody therapy over CAR T-cell therapy?
Unlike CAR T-cell therapy, which requires weeks to engineer a patient’s cells in a laboratory, bispecific antibodies are “off-the-shelf” treatments. This allows for immediate, streamlined access without manufacturing delays.
What is Cytokine Release Syndrome (CRS)?
Cytokine Release Syndrome (CRS) is a temporary immune reaction that can occur when T cells are rapidly activated. Symptoms may include fever, chills, low blood pressure, or difficulty breathing, and it is closely monitored and managed by your care team.
Where can I receive bispecific antibody therapy in New Jersey?
You can access bispecific antibody therapy through New Jersey Cancer Care, PA, where experienced oncologists provide treatment at local inpatient and outpatient facilities across New Jersey. Schedule an appointment today to discuss your treatment options.